NCT06398405View on ClinicalTrials.gov

A Phase II Clinical Study of Epigallocatechin-3-gallate in Patients With Esophageal Squamous Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

April 22, 2024

Primary Completion Date

April 22, 2026

Study Completion Date

May 22, 2026

Conditions
Esophageal CancerDysphagia, EsophagealEpigallocatechin Gallate
Interventions
OTHER

Epigallocatechin-3-gallate

Epigallocatechin-3-gallate is administered in a solution with a concentration of 4400 umol/L

Trial Locations (1)

250117

RECRUITING

Shandong Cancer Hospital, Jinan

All Listed Sponsors
lead

Shandong Cancer Hospital and Institute

OTHER